https://orcid.org/0000-0002-5267-2592
-
Views
-
Cite
Cite
Katie Dunleavy, Laura Raffals, Total Proctocolectomy Versus Subtotal/Total Colectomy for Neoplasia in Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases, 2025;, izaf003, https://doi.org/10.1093/ibd/izaf003
Close - Share Icon Share
Extract
To the Editors,
Thank you to Kaili et al. for sharing their thoughtful comments on our study, “Total Proctocolectomy vs Subtotal/Total Colectomy for Neoplasia in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.”1 We truly appreciate the feedback and wholeheartedly agree with many of the points raised regarding the study’s limitations.
We completely concur that prospective research and international multi-center collaborations are crucial for deepening our understanding of treatment outcomes in the primary sclerosing cholangitis and inflammatory bowel disease (PSC-IBD) patient population. As highlighted in our paper, the inherent biases and data limitations in retrospective studies underscore the need for future research with a more standardized approach to data collection and monitoring. We believe that by conducting prospective studies across multiple centers, we can not only reduce selection bias but also enhance the quality and reliability of the data, which will ultimately improve the generalizability of our findings. We are eager to explore collaborative opportunities in this regard.
